Entities / Company
Cidara Therapeutics.
company in San Diego, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 22
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
RBC boosted the price target for Cidara Therapeutics to $75.Speculative1 report
-
Cidara Therapeutics filed an offering with the U.S. Securities and Exchange Commission, with Morgan Stanley and Cantor acting as joint book-running managers.Some support4 reports
-
Cidara Therapeutics was included in the Russell 2000 and 3000 indexes on June 30, 2025.Speculative1 report
-
Cidara Therapeutics, based in San Diego, received Fast Track Designation from the FDA for its therapy CD388.Some support8 reports
No events began in the chosen period. Widen it, or reset.
Around Cidara Therapeutics this week
News at the entities that move Cidara Therapeutics most-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Cidara Therapeutics
-
SEC StructuralLaser Photonics Corporation hired Tim Peterman as Chief Financial Officer and engaged CBIZ for financial reporting consulting.Moves Cidara Therapeutics
-
Merck StructuralThe Schwab U.S. Dividend Equity ETF holds Abbott Laboratories, Merck, and Coca-Cola as among its top holdings.Moves Cidara Therapeutics
-
Morgan Stanley TransactionalCitigroup upgraded Next plc to a buy rating, while Santander and Morgan Stanley also issued rating updates on the company.Moves Cidara Therapeutics
-
San Diego Shared contextLuis de Lecea conducted early research in San Diego on October 20, 2026.Moves Cidara Therapeutics
Connections
The 6 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Cidara Therapeutics is subject to formal regulatory requirements and filing mandates imposed by the SEC.
-
FDA Structural
The FDA provides formal regulatory oversight and grants designations for Cidara Therapeutics' drug development.
-
Merck Structural
Merck acquired Cidara Therapeutics, establishing a current parent-subsidiary relationship.
-
MRK Operational
The relationship is characterized by active market competition, discussed alongside peer groups.
-
Morgan Stanley Transactional
Morgan Stanley served as the joint book-running manager for Cidara Therapeutics during a financing event.
-
San Diego Shared context
Cidara Therapeutics is headquartered in San Diego.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
1 eventJune 2026
4 events- RBC boosted the price target for Cidara Therapeutics to $75.
- Cidara Therapeutics filed an offering with the U.S. Securities and Exchange Commission, with Morgan Stanley and Cantor acting as joint book-running managers.
- Cidara Therapeutics was included in the Russell 2000 and 3000 indexes on June 30, 2025.
- Cidara Therapeutics, based in San Diego, received Fast Track Designation from the FDA for its therapy CD388.